Novartis AG ended Q2 on a high note. Despite declining sales of Entresto, the heart failure medicine

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

Novartis AG (NVS) Q2 2026 Earnings Call Transcript

Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong p

Novartis tops Q2 earnings and revenue estimates as growth from key brands offsets generic pressure,

GM, MMM, NVS, NOC, HAS and DHI all outperformed expectations on their quarterly reports this morning

Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by stro

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the qu

Novartis (NYSE:NVS) reported second-quarter financial results on Tuesday. The transcript from the co

Stock futures are rising after three straight days of declines for major indexes; chip stocks are le

Novartis AG (NYSE:NVS) reported better-than-expected second-quarter earnings on Tuesday as strong de

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats

Novartis chief executive ​officer Vas Narasimhan ‌said on Tuesday he plans ​to stick ​around for the

Companies Reporting Before The Bell • Mueller Industries (NYSE:MLI) is projected to report quarterly

Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-ex

Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling product

Novartis' second-quarter core operating profit beat ​market expectations on Tuesday, ‌helped by stro

Novartis (NYSE:NVS) reported quarterly earnings of $2.41 per share which beat the analyst consensus

Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum fr

While the first quarter showed weaker revenue and earnings, management had already warned that 2026

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yie

Dimensional Fund Advisors LP reduced its stake in shares of Novartis AG (NYSE: NVS) by 4.9% in the u

Boston Common Asset Management LLC lessened its position in shares of Novartis AG (NYSE: NVS) by 4.5

Novartis investors will look beyond Tuesday's quarterly results for indications about three major dr

NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney

Novartis wins traditional FDA approval for Fabhalta, a first-in-class oral treatment slowing kidney

Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some

IgAN is an autoimmune kidney disease that occurs when clumps of immunoglobulin A and antibodies are

Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors

Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen AD

https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-gener

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abepa

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-

Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class pr

Europe has eased deportation rules of illegal migrants in response to rising public frustration over

Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsi

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a poten

Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endp

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

https://www.novartis.com/news/media-releases/new-psmaddition-data-show-58-lower-risk-psa-progression

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

White House estimates Trump's drug pricing agreements could save $529 billion in next decade, bu

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefit

International ETFs are gaining momentum as global markets outperform US stocks. Here's what'

The complete list of Super Bowl 2026 commercials from Super Bowl LX and the companies behind the ads